Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Deferred Revenue (2024 - 2025)

Aclaris Therapeutics has reported Current Deferred Revenue over the past 2 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $3.9 million for Q4 2025, up 1.36% from a year ago — trailing twelve months through Dec 2025 was $3.9 million (up 1.36% YoY), and the annual figure for FY2025 was $3.9 million, up 1.36%.
  • Current Deferred Revenue for Q4 2025 was $3.9 million at Aclaris Therapeutics, roughly flat from $3.9 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ACRS hit a ceiling of $25.8 million in Q2 2024 and a floor of $3.8 million in Q3 2024.